Table 2.
Underlying diagnoses for LTx, comorbidities and immunosuppression at study start.
| LCPT (n = 61) |
Standard-Release Tac (n = 60) |
p-Value | |
|---|---|---|---|
| Principal diagnosis | 0.455 | ||
| Alcoholism | 9 (14.8%) | 16 (26.7%) | |
| Viral hepatitis | 15 (24.6%) | 15 (25.0%) | |
| Genetically related metabolic disease | 7 (11.5%) | 5 (8.3%) | |
| Toxic: nutritional or NASH | 3 (4.9%) | 1 (1.7%) | |
| Autoimmune liver disease | 11 (18.0%) | 13 (21.7%) | |
| Other | 16 (26.2%) | 10 (16.7%) | |
| Arterial hypertension | 36 (59.0%) | 37 (61.7%) | 0.853 |
| Diabetes mellitus | 18 (29.5%) | 17 (28.3%) | 1.000 |
| Hyperlipidaemia | 19 (31.1%) | 14 (23.3%) | 0.415 |
| CKD at study start | 0.598 | ||
| CKD 2 | 18 (29.5%) | 21 (35.0%) | |
| CKD 3a | 16 (26.2%) | 10 (16.7%) | |
| CKD 3b | 9 (14.8%) | 7 (11.7%) | |
| CKD 4 | 2 (3.3%) | 1 (1.7%) | |
| Tac formulation at study onset | <0.001 | ||
| Immediate-release Tac | 43 (70.5%) | 22 (36.7%) | |
| Extended-release Tac | 18 (29.5%) | 38 (63.3%) | |
| Co-immunosuppression | 0.060 | ||
| MMF | 34 (55.7%) | 35 (58.3%) | |
| Everolimus | 13 (21.3%) | 5 (8.3%) | |
| Prednisolone | 3 (4.9%) | 10 (16.7%) | |
| Sirolimus | 0 | 1 (1.7%) | |
| None | 11 (18.0%) | 9 (15.0%) | |
| Reasons for a switch to LCPT | |||
| CNIT | 7 | ||
| Neurotoxicity | 5 | ||
| Preventions of side effects | 49 |
Statistics: Values shown as number (percentage). All p-values from Fisher’s exact tests. LCPT, once-daily MeltDose® tacrolimus; Tac, tacrolimus; LTx, liver transplantation; NASH, nonalcoholic steatohepatitis; CKD, chronic kidney disease (categories set with reference to [23]). MMF, mycophenolate mofetil; CNIT, calcineurin inhibitor nephrotoxicity.